Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan

被引:1
|
作者
Hida, Tokimasa [1 ]
Idogawa, Masashi [2 ]
Kato, Junji [1 ]
Kiniwa, Yukiko [3 ]
Horimoto, Kohei [1 ]
Sato, Sayuri [1 ]
Sawada, Masahide [1 ]
Tange, Shoichiro [2 ]
Okura, Masae [1 ]
Okuyama, Ryuhei [3 ]
Tokino, Takashi [2 ]
Uhara, Hisashi [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Japan
[2] Sapporo Med Univ, Canc Res Inst, Sch Med, Dept Med Genome Sci, Sapporo, Japan
[3] Shinshu Univ, Sch Med, Dept Dermatol, Nagano, Japan
来源
CANCER MEDICINE | 2024年 / 13卷 / 22期
基金
日本学术振兴会;
关键词
DNA copy number variation; immune checkpoint inhibitor; melanoma; molecular targeted therapy; mutation; BRAF; DACARBAZINE; IPILIMUMAB; INHIBITORS; SURVIVAL; CANCER; NRAS;
D O I
10.1002/cam4.70360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAcral and mucosal melanomas are more prevalent in Asians than in Caucasians, unlike cutaneous melanomas, which are predominant in Caucasians. Recent studies have suggested that non-Caucasian cutaneous melanomas responded less to immune checkpoint inhibitors, highlighting the need for genetic profiling across ethnicities. This study aimed to elucidate the genetic characteristics of Japanese melanomas, which is an under-researched topic.MethodsSingle-nucleotide variants, indels, and copy number alterations in 104 Japanese melanoma patients (37 cutaneous, 52 acral, and 15 mucosal) were analyzed using custom panel sequencing.ResultsDriver events were detected in 94% of the cases. Among cutaneous melanoma cases, 76% had BRAF mutations, and 8% had NRAS mutations. In acral melanoma, BRAF (9%), NRAS (17%), KRAS (8%), KIT (19%), and NF1 (7%) mutations were detected. Major driver mutations in mucosal melanoma were detected in NRAS, KRAS, NF1, PTEN, GNAQ, and KIT. The median tumor mutational burden across all melanoma types was 4.6 mutations/Mb, with no significant difference between the cutaneous and acral/mucosal types. Of the 21 patients with both primary and metastatic lesions, 11 showed distinct mutations in each. Potentially actionable mutations were detected in 58 patients in addition to BRAF V600E/K mutations in 31.ConclusionsThis study highlights distinct genetic abnormalities and actionable alterations in Japanese melanoma patients. This suggests a lower tumor mutational burden in East Asian cutaneous melanoma, which may affect the efficacy of immune checkpoint inhibitors. The heterogeneity of driver mutations across and within individuals highlights the need for personalized treatment approaches.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients
    Maeda, T.
    Yoshino, K.
    Nagai, K.
    Oaku, S.
    Kato, M.
    Hiura, A.
    Hata, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1230 - 1231
  • [32] Lymphatic invasion in acral and non-acral melanoma: a comparative, clinicoprognostic study of primary cutaneous melanoma according to tumour site
    Jung, Joon Min
    Won, Chong Hyun
    Chang, Sung Eun
    Lee, Mi Woo
    Choi, Jee Ho
    Lee, Woo Jin
    PATHOLOGY, 2020, 52 (06) : 670 - 675
  • [33] The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Kuk, Deborah
    Ott, Patrick A.
    Johnson, Douglas B.
    Tsai, Katy K.
    Rapisuwon, Suthee
    Eroglu, Zeynep
    Sullivan, Ryan J.
    Luke, Jason J.
    Gangadhar, Tara C.
    Salama, April K. S.
    Clark, Varina
    Burias, Clare
    Puzanov, Igor
    Atkins, Michael B.
    Algazi, Alain P.
    Ribas, Antoni
    Wolchok, Jedd D.
    Postow, Michael A.
    CANCER, 2016, 122 (21) : 3354 - 3362
  • [34] KIT Gene Mutations and Patterns of Protein Expression in Mucosal and Acral Melanoma
    Abu-Abed, Suzan
    Pennell, Nancy
    Petrella, Teresa
    Wright, Frances
    Seth, Arun
    Hanna, Wedad
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2012, 16 (02) : 135 - 142
  • [35] Classification of Cutaneous Melanoma and Melanocytic Nevi with MicroRNA Ratios Is Preserved in the Acral Melanoma Subtype
    Deacon, Dekker C.
    Stubben, Chris
    Marcacci, Eleonora
    Stone, Caroline J.
    Birdsall, Michael
    Florell, Scott R.
    Boucher, Ken
    Grossman, Douglas
    Judson-Torres, Robert L.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2025, 145 (03)
  • [36] Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma
    Buchbinder, Elizabeth I.
    Sosman, Jeffrey A.
    Lawrence, Donald P.
    McDermott, David F.
    Ramaiya, Nikhil H.
    Van den Abbeele, Annick D.
    Linette, Gerald P.
    Giobbie-Hurder, Anita
    Hodi, F. Stephen
    CANCER, 2015, 121 (22) : 4007 - 4015
  • [37] Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
    Klemen, Nicholas D.
    Wang, Melinda
    Rubinstein, Jill C.
    Olino, Kelly
    Clune, James
    Ariyan, Stephan
    Cha, Charles
    Weiss, Sarah A.
    Kluger, Harriet M.
    Sznol, Mario
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [38] Oral mucosal melanoma: not the same as the cutaneous variant
    O'Gorman, Conor
    Graham, Laura
    Pajpani, Meera
    Beresford, Amanda
    Napier, Seamus
    Adair, Stephen
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 33 - 33
  • [39] Brain PET/CT in Cutaneous or Mucosal Melanoma
    Asabella, A. Niccoli
    Santoro, P.
    Altieri, M. L.
    Montemurro, I.
    Rubini, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S274 - S274
  • [40] Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan
    Wada, Maiko
    Ito, Takamichi
    Tsuji, Gaku
    Nakahara, Takeshi
    Hagihara, Akihito
    Furue, Masutaka
    Uchi, Hiroshi
    JOURNAL OF DERMATOLOGY, 2017, 44 (08): : 932 - 938